Overview

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.

Phase:

Phase 2

Details

Lead Sponsor:

Reata Pharmaceuticals, Inc.